Core Viewpoint - The company has completed the registration of changes in its business license following the reduction of registered capital through the cancellation of repurchased shares [1][2][3] Group 1: Share Repurchase and Capital Reduction - The company held board meetings on April 25, 2025, and May 26, 2025, to approve the change of purpose for repurchased shares totaling 44,853,573 shares and 6,620,630 shares, respectively, to "reduce registered capital" [1][2] - The company completed the cancellation of repurchased shares on August 12, 2025, as per the announcements made on the Shanghai Stock Exchange [2] Group 2: Business Registration Changes - The company has successfully completed the business registration change and received a new business license from the Heze Market Supervision Administration [3] - The updated registered capital is RMB 1,054,484,432 [3] - The company operates in the production of various pharmaceutical forms, including tablets, hard capsules, granules, and oral liquids [3]

Group 1 - The company, Hangzhou Tian-Mu-Shan Pharmaceutical Co., Ltd., was established as a pilot unit for state-owned enterprise reform in October 1989 and has undergone several regulatory updates since then [2][3][4] - The registered capital of the company is RMB 121.78 million, and it operates as a permanent joint-stock company [4][5] - The company aims to develop a modern enterprise group with first-class economic benefits and products, focusing on pharmaceutical production and diversified development [3][4] Group 2 - The company has established a party organization to play a political core role and provide political guidance in its development [2] - The company’s business scope includes the production of various pharmaceutical forms, health foods, medical devices, and cosmetics, among others [3][4] Group 3 - The company issues shares in the form of stocks, with each share having a face value of RMB 1 [4][5] - The total number of shares issued by the company is 121,778,885, all of which are ordinary shares [4][5] Group 4 - The company is prohibited from providing financial assistance for others to acquire its shares, except under specific circumstances approved by the shareholders' meeting [5][6] - The company can reduce its registered capital following legal procedures and shareholder approval [6][7] Group 5 - The company’s shareholders have rights to dividends, voting, and other benefits proportional to their shareholdings [10][11] - Shareholders holding more than 5% of the shares must declare their holdings and any changes [8][9] Group 6 - The company’s shareholders' meeting is the authority of the company, responsible for electing directors, approving financial reports, and making significant corporate decisions [18][19] - The company must hold an annual shareholders' meeting within six months after the end of the previous fiscal year [21][22]

中证报中证网讯（记者 张鹏飞）5月27日，中华老字号中药企业宏济堂丸剂数智工厂进入试生产，这标 志着宏济堂在丸剂智能制造领域取得重大突破。宏济堂为科源制药（301281）拟收购标的。 作为拥有118年历史的中华老字号企业，宏济堂目前持有的150余个文号中，91个为丸剂品种，形成蜜 丸、水丸、水蜜丸、糊丸、浓缩丸五大丸剂体系，构建起国内领先的传统丸剂矩阵。宏济堂董事长蒋红 升表示，面对市场对高品质丸剂产品的旺盛需求以及传统生产模式在效率、质量管控上的局限，宏济堂 制药前瞻性布局，投资建设丸剂数智工厂，旨在通过科技创新实现生产流程的革新，推动中医药产业迈 向现代化发展新高度。 据悉，宏济堂制药丸剂数智工厂建筑面积达1.2万平方米，入选省级重点项目。项目致力于丸剂全工艺 生产过程的技术升级，以5G工业互联网为依托，以AI技术为核心驱动力，融合数智孪生和前沿工艺技 术、精准的质量管控体系，构建起端到端智能体系，形成中医药生产大数据资产，将传统中药生产升级 为"数据驱动、精准可控"的现代化模式，实现丸剂连续化、智能化制造，全力打造智能、绿色、透明工 厂。 宏济堂丸剂数智工厂首创六角形锦缎盒全自动包装产线，实现了包装流程 ...